GlassScriptPhysician profile
Timothy Terrell Lanier
NPI 1992459457
$3,513.45
in general payments reported to CMS, 2019-2025
18 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $339 · 2023: $1,041 · 2024: $939 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $993.86 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $640.27 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $621.90 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $195.07 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Ardelyx, INC. | $188.16 | 2023-2024 | Ibsrela |
| Novo Nordisk INC | $155.04 | 2024-2025 | Ozempic, Rybelsus |
| Intra-Sana Laboratories | $141.17 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.93 | 2024 | Jardiance |
| Urovant Sciences INC | $111.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $105.10 | 2022-2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $48.77 | 2023 | |
| Renalytix Ai, INC. | $34.01 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Lundbeck LLC | $31.38 | 2025 | Rexulti |
| Gilead Sciences, INC. | $30.45 | 2025 | |
| Pfizer INC. | $28.49 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24.71 | 2025 | Korlym |
| Abiomed | $19.70 | 2025 | |
| Abbott Laboratories | $17.25 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.